Skip to main content
Clinical Trials/NCT07410546
NCT07410546
Not yet recruiting
Not Applicable

Role of Quantitative Fecal Immunochemical Test as a Diagnostic Tool in Evaluation of Site and Type of Colorectal Cancer and Precancerous Lesions in Sohag Government

Sohag University0 sites150 target enrollmentStarted: February 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
150
Primary Endpoint
Diagnostic Accuracy of Quantitative Fecal Immunochemical Test

Overview

Brief Summary

Colorectal cancer is a major cause of cancer-related morbidity and mortality worldwide, and early detection significantly improves patient outcomes. The fecal immunochemical test (FIT) is a non-invasive stool-based test used for detection of colorectal cancer; however, its diagnostic performance varies according to lesion type and anatomical location.

This prospective observational cohort study aims to evaluate the diagnostic accuracy of quantitative fecal immunochemical testing (qFIT) in detecting colorectal cancer and precancerous lesions, including advanced adenomas and sessile serrated lesions, in adults undergoing colonoscopy in Sohag Government. The study will assess the sensitivity, specificity, and optimal cutoff values of qFIT according to lesion type, location, and histopathological characteristics.

Detailed Description

This is a prospective observational cohort study conducted at a tertiary care endoscopy unit in Sohag Government. Adult patients aged 40 to 75 years who are referred for diagnostic or screening colonoscopy will be invited to participate.

All eligible participants will provide a stool sample for quantitative fecal immunochemical testing (qFIT) prior to bowel preparation. Fecal hemoglobin concentration will be measured using a quantitative FIT assay and expressed as micrograms of hemoglobin per gram of stool.

All participants will subsequently undergo colonoscopy as part of routine clinical care. Colonoscopic findings will be recorded, including lesion presence, anatomical location (proximal colon, distal colon, or rectum), size, and morphology. Biopsy or polypectomy specimens will be examined histopathologically to confirm colorectal cancer, advanced adenomas, or sessile serrated lesions.

The diagnostic performance of qFIT will be evaluated by calculating sensitivity, specificity, positive predictive value, and negative predictive value for detection of colorectal cancer and precancerous lesions. Receiver operating characteristic (ROC) curve analysis will be used to determine optimal qFIT cutoff values according to lesion type and anatomical location. Associations between qFIT levels and lesion characteristics will also be analyzed.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Adults aged 40 to 75 years
  • Individuals undergoing screening or diagnostic colonoscopy
  • Participants able to provide informed consent

Exclusion Criteria

  • Age below 40 years or above 75 years
  • History of colorectal surgery
  • Inflammatory bowel disease
  • Inadequate bowel preparation
  • Refusal to participate

Arms & Interventions

Colorectal Cancer

Participants diagnosed with colorectal cancer confirmed by colonoscopy and histopathological examination.

Precancerous Lesions

Participants diagnosed with precancerous colorectal lesions, including advanced adenomas or sessile serrated lesions, confirmed by colonoscopy and histopathology.

Normal Colonoscopy

Participants with normal colonoscopy findings and no evidence of colorectal cancer or precancerous lesions.

Outcomes

Primary Outcomes

Diagnostic Accuracy of Quantitative Fecal Immunochemical Test

Time Frame: Up to 1 day

Assessment of the diagnostic accuracy of quantitative fecal immunochemical testing (qFIT) for detection of colorectal cancer and precancerous colorectal lesions, expressed as sensitivity, specificity, positive predictive value, and negative predictive value, using colonoscopy and histopathology as the reference standard.

Secondary Outcomes

  • Diagnostic Performance of qFIT by Lesion Type(Up to 1 day)
  • Diagnostic Performance of qFIT by Lesion Location(Up to 1 day)
  • Correlation Between qFIT Level and Lesion Characteristics(Up to 1 day)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Pierre Isac Ibrahim

Resident, Department of Internal Medicine, Faculty of Medicine, Sohag University

Sohag University

Similar Trials